CoChat

Increasing lean muscle mass in mice via nanoparticle-mediated hepatic delivery of follistatin mRNA

Open access
Schumann, Canan, Nguyen, Duc X., Norgard, Mason, Bortnyak, Yulia, Korzun, Tetiana, Chan, Stephanie, Lorenz, Anna St., Moses, Abraham S., Albarqi, Hassan A., Wong, Leon, Michaelis, Katherine, Zhu, Xinxia, Alani, Adam W. G., Taratula, Olena R., Krasnow, Stephanie, Marks, Daniel L., Taratula, Oleh · 2018 · Theranostics
Cited by 42

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Muscle atrophy occurs during chronic diseases, resulting in diminished quality of life and compromised treatment outcomes.There is a high demand for therapeutics that increase muscle mass while abrogating the need for special dietary and exercise requirements.Therefore, we developed an efficient nanomedicine approach capable of increasing muscle mass.Methods: The therapy is based on nanoparticle-mediated delivery of follistatin messenger RNA (mRNA) to the liver after subcutaneous administration.The delivered mRNA directs hepatic cellular machinery to produce follistatin, a glycoprotein that increases lean mass through inhibition of negative regulators of muscle mass (myostatin and activin A).These factors are elevated in numerous disease states, thereby providing a target for therapeutic intervention.Results: Animal studies validated that mRNA-loaded nanoparticles enter systemic circulation following subcutaneous injection, accumulate and internalize in the liver, where the mRNA is translated into follistatin.Follistatin serum levels were elevated for 72 h post injection and efficiently reduced activin A and myostatin serum concentrations.After eight weeks of repeated injections, the lean mass of mice in the treatment group was ~10% higher when compared to that of the controls.Conclusion: Based on the obtained results demonstrating an increased muscle mass as well as restricted fat accumulation, this nanoplatform might be a milestone in the development of mRNA technologies and the treatment of muscle wasting disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7150/thno.27847

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

Metadata

Authors
Schumann, C., Nguyen, D. X., Norgard, M., Bortnyak, Y., Korzun, T., Chan, S., Lorenz, A. S., Moses, A. S., Albarqi, H. A., Wong, L., Michaelis, K., Zhu, X., Alani, A. W. G., Taratula, O. R., Krasnow, S., Marks, D. L., & Taratula, O.
Venue
Theranostics
Published
2018
Volume
8
Issue
19
Pages
5276-5288
ISSN
1838-7640 (ISSN-L)
OpenAlex
W2899296642
Cited by
42
References
18
FWCI
1.26
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.